top of page



A Phase 2, Multicenter, Open-Label, Randomized Study Comparing INCB050465, a PI3K Inhibitor, to Idelalisib in Relapsed or Refractory Follicular Lymphoma.

Do you Qualify?

​These questions require a yes answer to qualify.​

  • Are you at least 18 years of age?

  • Have you been treated with at least 2  prior systemic therapies?

  • Are you willing to undergo an incisional, excisional, or core needle lymph node or tissue biopsy or provide a lymph node or tissue biopsy from the most recent available archival tissue?

​These questions require a no answer to qualify.​

  • Do you have a history of central nervous system lymphoma?

  • Have you ever had treatment with Idelalisib, pan-PI3K Inhibitor or treatment with a Bruton's Tyrosine Kinase inhibitor, (e.g: Ibrutinib)?

  • Have you ever tested positive for Hep B or Hep C?

If you think you may be eligible for this trial, please give us a call to schedule an appointment or click button below to email a request.

bottom of page